Safety and Immune Response of H5N1 Vaccine in Children
Author Information
Author(s): Chotpitayasunondh Tawee, Thisyakorn Usa, Pancharoen Chitsanu, Pepin Stephanie, Nougarede Nolwenn
Primary Institution: Queen Sirikit National Institute of Child Health, Bangkok, Thailand
Hypothesis
The study assesses the safety and immunogenicity of two formulations of an inactivated H5N1 vaccine in children.
Conclusion
The H5N1 vaccine was well tolerated and immunogenic in children, with the adjuvanted formulation showing a clear immunogenic advantage.
Supporting Evidence
- The 30 µg+Al formulation was more immunogenic than the 7.5 µg formulation.
- 79% of children receiving the adjuvanted vaccine had protective antibody levels after vaccination.
- No serious adverse events were reported during the trial.
- The study included a diverse age range of children from 6 months to 17 years.
Takeaway
The study tested a flu vaccine on kids and found it safe and effective, especially when it had an extra ingredient to boost the immune response.
Methodology
A Phase II, open, randomised, multicentre trial where 240 children received two injections of either adjuvanted or non-adjuvanted H5N1 vaccine.
Potential Biases
Potential bias due to the involvement of the study sponsor in protocol design and data analysis.
Limitations
The study did not include long-term follow-up data on immune responses or efficacy against actual H5N1 infection.
Participant Demographics
Healthy children aged 6 months to 17 years, with a gender distribution of approximately 47.9% male.
Statistical Information
Confidence Interval
95% CI: 46–67
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website